|Payment & Shipping Terms||Supply Capacity|
|Payment Terms:||L/C, T/T, WU||Production Capacity:||100 kg/Year|
|Min. Order:||50 Gram||Packing:||According to customer...|
|Means of Transport:||Ocean, Air, Land||Delivery Date:||Within 7 days|
Miripla (CAS: 141977-79-9)
Appliacation: The new liver cancer medicine
Appearance: white powder
Platinum (Miriplatin Hydrate) was developed by Japan's sumitomo pharmaceutical co., fat-soluble anticancer medicine, platinum complex on October 16, 2009, approved by Japan's health ministry, used in the treatment of hepatocellular carcinoma (HCC). On January 20, 2010, Miriplatin Hydrate and its special mixed suspension on sale at the same time.
Efficacy and pharmacological
Use in the liver transplantation rat liver cancer cell lines AH109A or human liver cell line of Li - seven mice transplanted liver cancer model, evaluation m platinum mixed suspension inhibition of cancer cell proliferation in the body. Platinum mixed suspension, according to the results of meters to inhibit cancer cell proliferation, dose related way and when mixed suspension of meters platinum is 20 mg/mL of tumor cell proliferation rate significantly reduced. M platinum suspension liquid is administered a single dose, for the same model of liver cancer has antitumor dose related.
Category: Antineoplastic Drugs API